TI
AUPH icon

tru Independence’s Aurinia Pharmaceuticals AUPH Stock Holding History

tru Independence’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-8,900
Closed -$145 – 354
2020
Q2 		$145 Buy
8,900
+800
+10% +$12.8K 0.02% 274
2020
Q1 		$118 Hold
8,100
– – 0.02% 235
2019
Q4 		$118K Buy
+8,100
New +$74.6K 0.02% 288

Other funds holding AUPH

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

tru Independence's AUPH Position: Q3 2020 in Review

tru Independence sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2020, closing a stake of 8,900 shares — an estimated $145 sold.

tru Independence first reported a position in AUPH in Q4 2019 and held it in 3 quarters. The position peaked at $118K in Q4 2019. 145 funds tracked by Wall St. Rank hold AUPH as of Q3 2020.

  • tru Independence reported no remaining Aurinia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • tru Independence sold 8,900 Aurinia Pharmaceuticals shares in Q3 2020, an estimated $145.
  • tru Independence first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • tru Independence's Aurinia Pharmaceuticals position peaked at $118K in Q4 2019.
  • 145 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2020.

Based on tru Independence's 13F filing for Q3 2020, filed 19 Nov 2020.